伴t(14;18)(q32;q21)慢性淋巴细胞白血病八例报告
回顾性分析江苏省人民医院2009年11月至2019年11月收治的8例伴t(14;18)(q32;q21)的慢性淋巴细胞白血病(CLL)患者临床资料并复习文献。结果显示该异常在CLL中少见,常伴+12和突变型IGHV,中位随访30.9个月时多数患者存活,提示预后可能良好。
要点
- 伴t(14;18)(q32;q21)的CLL少见,常合并+12和突变型IGHV。
- 8例中7例男性,诊断中位年龄70岁,随访30.9个月仅1例死亡。
- 4例接受化疗或免疫治疗者病情稳定,3例尚未达治疗指征。
核心结论
- t(14;18)(q32;q21)在CLL中少见,常与+12及突变型IGHV伴随出现。
- 伴t(14;18)(q32;q21)的CLL可能预后良好。
研究设计与样本
- 单中心回顾性病例分析,纳入2009年11月至2019年11月江苏省人民医院8例伴t(14;18)(q32;q21)的CLL患者,并进行文献复习。
主要发现
- 8例中7例男性、1例女性,诊断时中位年龄70岁。
- 免疫表型积分5分3例、4分4例、3分1例,骨髓组织病理均为典型CLL表现。
- 核型分析示t(14;18)(q32;q21)均为干系:3例为唯一异常,4例伴+12,1例伴13q-。
- FISH在另外3例患者中检出13q-。
- 6例检测IGHV突变状态均为有突变,未见IGHV3-21使用;仅1例携带TP53突变。
临床怎么用
- 对CLL患者检出t(14;18)(q32;q21)时,可结合+12、IGHV突变状态等评估,提示预后可能良好。
局限性
- 样本量仅8例,为单中心回顾性研究,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The study aimed to analyze the clinical features and prognosis of chronic lymphocytic leukemia (CLL) with t (14;18) (q32;q21) and conduct a literature review. Methods: The clinical data of 8 patients with CLL carrying t (14;18) (q32;q21) seen in Jiangsu Province Hospital from November 2009 to November 2019 were collected and analyzed. Results: Among the 8 cases, 7 were male and 1 was female. The median age at diagnosis was 70 years old. The immunophenotype score was 5 in 3 patients. 4 patients were scored 4 and the remaining one scored 3. The bone marrow histopathology showed the typical manifestation of CLL. Karyotype analysis showed that all the cases carried t (14;18) (q32;q21) in the stemline. The t (14;18) (q32;q21) showed as the sole abnormality in 3 cases, with +12 in 4, and with 13q- in 1 case. 13q- was found in another 3 patients by FISH. Immunoglobulin heavy chain gene (IGHV) mutation status was detected in 6 cases and all of them were mutated. None of them used IGHV3-21. Only 1 case harbored TP53 mutation and no TP53, SF3B1, NOTCH1, or MYD88 mutations were found in the remaining cases who underwent the relevant tests. At a median follow-up of 30.9 months, 1 case died. The remaining 7 cases survived and 3 of them have not reached the treatment indication. 4 patients who received chemotherapy or immunotherapy were stable. Conclusions: The t (14;18) (q32;q21) is rare in CLL and often accompanied by +12 and mutated IGHV. CLL with t (14; 18) (q32; q21) tends to have a good prognosis. 目的: 分析伴t(14;18)(q32;q21)的慢性淋巴细胞白血病(CLL)患者的临床特征及预后,并进行相关文献复习。 方法: 收集并分析2009年11月至2019年11月于江苏省人民医院就诊的8例伴t(14;18)(q32;q21)的CLL患者的临床资料。 结果: 8例患者中7例男性,1例女性,诊断时中位年龄70岁,3例免疫表型积分5分,4例积分4分,1例积分3分。所有患者的骨髓组织病理学均为典型CLL表现。染色体核型示所有患者的t(14;18)(q32;q21)均为干系,3例仅携带t(14;18)(q32;q21)异常,4例为t(14;18)(q32;q21)伴+12,1例为t(14;18)(q32;q21)伴13q-。通过FISH在另外3例患者中发现了13q-。6例检测了免疫球蛋白重链可变区(IGHV)突变状态且均为有突变,未见IGHV3-21片段使用。进行相关检测的患者中,仅1例携带TP53突变,其余患者未见TP53、SF3B1、NOTCH1、MYD88突变。中位随访30.9个月时,1例死亡,7例存活,其中3例尚未达到治疗指征,4例接受化疗或免疫治疗的患者病情均稳定。 结论: t(14;18)(q32;q21)在CLL中少见,往往与+12、有突变的IGHV伴随出现。伴t(14;18)(q32;q21)的CLL可能预后良好。.
引用
- Li J, Zhang HR, Qiu H, et al. [Chronic lymphocytic leukemia with t (14;18) (q32;q21) : report of eight cases and a literature review]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34455745. doi:10.3760/cma.j.issn.0253-2727.2021.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。